Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events

Table 4 Frequency of specific immune-related adverse events

Immune-related adverse event	G1/2, n (%)	G3/4, n (%)
Skin (rash)	3 (13.0%)	0
Arthritis	3 (13.0%)	0
Colitis	0	2 (8.7%)
Encephalitis	0	2 (8.7%)
Hypothyroidism	1 (4.3%)	0
Pneumonitis	0	1 (4.3%)
Neuropathy	0	1 (4.3%)